Abstract:Objective To investigate the relationship among age,menopausal status,serum 25 (OH)VD and skeletal metabolism index as PTH (Parathyroid Hormone),CA(Calcium),P (Phosphorus) and boned mineral density (BMD) of climacteric female in Xi'an.Methods 352 cases of healthy women at the age of 40～60 were collected who did routine examination in outpatient building of the First Affiliated Hospital of Xi'an Jiaotong University from January 2016 to April 2016.According to the results of skeletal density test,all subjects were divided into 3 groups as the normal group (T＞-1),the reduction group (-2.5＜T＜-1),the osteoporosis group (T＜-2.5).Electrochemiluminescent immunoassay (ECLIA) was used to detect levels of serum 25 (OH)VD,PTH,CA and P.Kruskal-Wallis test and chi-square test were used to analyze differences of age,serum 25(OH)VD,PTH,CA and P in different levels of bone mineral density groups.Results Compared with bone density normal group 2.24(2.18～2.29)mmol/L,serum CA levels of bone mineral density reduction group 2.27 (2.20 ～ 2.32)mmol/L and osteoporosis group 2.27(2.23～2.33)mmol/L were significantly higher (Z=9.669,P＜0.01).Serum P levels of bone mineral density reduction group 1.15 (1.09～ 1.23)mmol/L and osteoporosis group 1.18 (1.09～ 1.25)mmol/L were obviously higher than bone density normal group,1.11 (0.99 ～ 1.23) mmol/L (Z =13.64,P＜ 0.01).Ages of osteoporosis group 54(50～57) years and bone mineral density reduction group 51 (47～ 54) years were significantly older than Bone density normal group 47(43～50) years (Z=73.08,P＜0.01).The rate of menopause in osteoporosis group and bone mineral density reduction group were significantly higher than in bone density normal group (x2 =13.81,P＜ 0.01).There was no statistical difference in serum 25(OH)VD and PTH between groups.Conclusion This study found boned density of climacteric women is more likely correlated with age,menopause status and levels of serum CA and P.There was not enough evidence to prove that 25 (OH)VD and PTH have effect on skeletal density.Therefore,to monitor and detect the menopause status and levels of serum CA and P of climacteric female is critical for the prevention and treatment on osteoporosis of women.

Clinical research on which age group calcitonin treatment can benefit most

Clinical observiation on calcitonin in management of osteoporosis

Research and Application of Target Therapy for Osteoporosis

Clinical efficacy and outcomes of calcitriol combined with bisphosphonates in the treatment of postmenopausal osteoporosis: A quasi-experimental study

The Efficacy and Safety of Calcitriol And/or Caltrate D in Elderly Chinese Women with Low Bone Mass

The Effects of Calcitonin Treatment on Bone Quality in Patients Withosteoporosis

Evaluation of Boned Metabolism Quota in the Prediction of Osteoporosis of Climacteric Female in Xi' an Area

Age-related Changes of Serum Bone Alkaline Phosphatase and Cross-Linked C-telopeptides of Type I Collagen and the Relationship with Bone Mineral Density in Chinese Women

Analysis the effect of salmon calcitonin combined with azole phosphonic acid in the treatment of osteoporosis in elderly men

Clinical Efficacy Observation of Recombinant Human Parathyroid Hormone 1-34(Rhpth1-34)combined with Caltrate D in Treatment of Post Menopausal Women with Osteoporosis

Clinical Effects of Miacalcic and Drug Combination in Treating Middle-aged and Elderly Patients with Osteoporosis Fracture

The effect of salmon calcitonin on bone mineral density and bone BALP,CICP,CTX-I expression in elderly patients with osteoporotic fracture

Age-related Changes of Serum Tartrate-Resistant Acid Phosphatase 5b and the Relationship with Bone Mineral Density in Chinese Women

Correlation between BMD and TRACP,CTX-1,BALP,BGP,calcium,and phosphorus in 1084 women

Efficacy of recombinant human parathyroid hormone 1-34(rhPTH1-34) in post-menopausal osteoporosis

The study of the relationships among bone mineral density,bone biochemical markers,and osteoporotic fractures in senior patients with primary osteoporosis

Serum 25-Hydroxyvitamin D, Bone Turnover Markers and Bone Mineral Density in Postmenopausal Women with Hip Fractures.

Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment

Relationship between Bone Biochemical Markers and Bone Mineral Density at Hip in the Female

Effects of calcitriol on the static balance function in postmenopausal osteoporotic women

Changes of Biochemical Markers of Bone Turnover and Bone Mineral Density in Mid- and Old-Aged Women